Search research articles
Contact Us
Filters
Showing results (21-30 of 77) with videos related to
Page
of 8
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2013
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials
Charles Ferté, Marianna Fernandez, Antoine Hollebecque, et al.
Investigational New Drugs
|
April 22, 2011
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Investigational New Drugs
|
November 4, 2024
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
Mathilde Morisseau, Carlos Gomez-Roca, Marie Viala, et al.
Cancer Discovery
|
March 16, 2016
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, et al.
Investigational New Drugs
|
November 10, 2018
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elena Elez, Carlos Gomez-Roca, Arturo Soto Matos-Pita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Carlos Gomez-Roca, Christophe M Raynaud, Frederique Penault-Llorca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2021
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
BMJ Oncology
|
February 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours
Carlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos, et al.
Science Immunology
|
June 8, 2023
Distant antimetastatic effect of enterotropic colon cancer-derived α4β7
Virginie Feliu, Carlos Gomez-Roca, Marie Michelas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2017
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, et al.
Page
of 8
Search research articles
Search
Showing results (21-30 of 77) with videos related to
Sort By:
Page
of 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
November 19, 2013
Tumor growth rate is an early indicator of antitumor drug activity in phase I clinical trials
Charles Ferté, Marianna Fernandez, Antoine Hollebecque, et al.
Investigational New Drugs
|
April 22, 2011
Reappraisal of treatment-induced renal dysfunction in patients receiving antiangiogenic agents in phase I trials
Antonin Levy, Laurence Albiges-Sauvin, Christophe Massard, et al.
Investigational New Drugs
|
November 4, 2024
Modernizing the assessment and reporting of adverse events in oncology clinical trials using complementary statistical approaches: a case study of the MOTIVATE trial
Mathilde Morisseau, Carlos Gomez-Roca, Marie Viala, et al.
Cancer Discovery
|
March 16, 2016
Clinical Response of Carcinomas Harboring the BRD4-NUT Oncoprotein to the Targeted Bromodomain Inhibitor OTX015/MK-8628
Anastasios Stathis, Emanuele Zucca, Mohamed Bekradda, et al.
Investigational New Drugs
|
November 10, 2018
First-in-human phase I study of the microtubule inhibitor plocabulin in patients with advanced solid tumors
Elena Elez, Carlos Gomez-Roca, Arturo Soto Matos-Pita, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer
|
August 19, 2009
Differential expression of biomarkers in primary non-small cell lung cancer and metastatic sites
Carlos Gomez-Roca, Christophe M Raynaud, Frederique Penault-Llorca, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
January 26, 2021
Regorafenib-Avelumab Combination in Patients with Microsatellite Stable Colorectal Cancer (REGOMUNE): A Single-arm, Open-label, Phase II Trial
Sophie Cousin, Coralie Cantarel, Jean-Philippe Guegan, et al.
BMJ Oncology
|
February 25, 2026
First-in-human phase 1 dose-escalation study of W0180, an anti-VISTA monoclonal antibody, with and without pembrolizumab in patients with locally advanced or metastatic solid tumours
Carlos Gomez-Roca, Stéphane Champiat, Francois-Xavier Danlos, et al.
Science Immunology
|
June 8, 2023
Distant antimetastatic effect of enterotropic colon cancer-derived α4β7
Virginie Feliu, Carlos Gomez-Roca, Marie Michelas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 3, 2017
Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial
Jean-Sebastien Frenel, Christophe Le Tourneau, Bert O'Neil, et al.
Page
of 8